Tau assemblies become seed-competent when their repeat-domain surfaces adopt a conformation that both survives transfer and templates monomeric tau into pathological aggregates. This conformer-specific templating mechanism, supported by structural studies of disease-specific tau filaments, suggests that the exposed repeat domain interface is the critical determinant distinguishing pathogenic from non-pathogenic tau conformations. Non-pathogenic transferred tau lacks this exposed templating interface despite similar uptake, indicating that cellular internalization alone is insufficient for prion-like propagation. The probabilistic model of Alzheimer disease revised in 2022 suggests that such templated aggregation processes may be central to disease progression.
...
Tau assemblies become seed-competent when their repeat-domain surfaces adopt a conformation that both survives transfer and templates monomeric tau into pathological aggregates. This conformer-specific templating mechanism, supported by structural studies of disease-specific tau filaments, suggests that the exposed repeat domain interface is the critical determinant distinguishing pathogenic from non-pathogenic tau conformations. Non-pathogenic transferred tau lacks this exposed templating interface despite similar uptake, indicating that cellular internalization alone is insufficient for prion-like propagation. The probabilistic model of Alzheimer disease revised in 2022 suggests that such templated aggregation processes may be central to disease progression. Conformational exposure of the repeat domain thus defines seed-competent tau conformers and may represent a therapeutic target for preventing the establishment of the templating interface required for neurodegeneration.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["MAPT tau protein"]
B["Repeat domain conformational change"]
C["Exposed templating interface"]
D["Seed-competent tau conformer"]
E["Templating of monomeric tau"]
F["Survival during intercellular transfer"]
G["Non-pathogenic tau conformer"]
H["Lacks exposed interface"]
I["Propagation of tau aggregates"]
J["Neurodegeneration"]
A --> B
B --> C
C --> D
C --> G
D --> E
D --> F
E --> I
F --> I
I --> J
G --> H
H -.->|"No templating"| G
Median TPM across 13 brain regions for MAPT from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations7 with PMID5 mediumValidation: 72%8 supporting / 2 opposing
✓For(8)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
3
MECH 5CLIN 2GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
MAPT mutations, tauopathy, and mechanisms of neuro…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Seed-competent tau is likely defined by a compact beta-rich conformer exposing repeat-domain surfaces, a permissive PTM barcode, and packaging into vesicles or synaptic compartments that protect it from degradation during transfer.
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Uptake is not seeding. The decisive experiment must compare matched tau species that enter neurons equally but differ in templating kinetics, persistence, and downstream neurotoxicity.
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Clinically, the best product concept is a conformation- or PTM-selective antibody paired with CSF seed amplification or tau-PET enrichment. Broad tau lowering risks interfering with normal microtubule biology.
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Ranked synthesis: conformer exposure is primary, PTM barcode is the strongest modulator, and vesicle context explains why some transferable tau remains non-pathogenic.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.